HGH Fragment 191-203 – Kodiac biolabs

Our opinion on this compoundNiche research probe

31/100

Dated GH fragment with debated mechanism; clinical derivative AOD9604 failed Phase 2 on insufficient effect size

Look, Fragment 191-203 has a genuinely interesting conceptual story. The idea is clean: take the C-terminal stretch of growth hormone, isolate the lipolytic activity, and leave behind the somatogenic effects, the IGF-1 elevation, and the chronic insulin resistance that comes with full GH exposure. Thats a real and sensible pharmacological goal. The problem is that the compound never made good on it at the level that matters.

The mechanism starts interesting. The fragment appears to engage beta-3 adrenergic pathways or downstream lipolytic signaling at the adipocyte level without activating the full GH receptor complex, which is why IGF-1 stays quiet and somatogenic activity is absent. No GH receptor engagement. No growth-promoting baggage. That’s the whole pitch. But the mechanism was never nailed down cleanly. The beta-3 adrenergic story is plausible, but two-plus decades later it remains contested. That isnt a good sign for a compound that had its main research window in the Clinton era.

The evidence base is dated. The foundational work is rodent adipocyte studies and obese rodent in vivo models, most of it published in the 1990s and early 2000s by a handful of groups. Old data isn’t inherently disqualifying; some compounds with solid older literature remain genuinely useful tools. But the clinical translation test came and went. Metabolic Pharmaceuticals took the more-developed cousin, AOD9604, a tyrosine-conjugated 16-residue version, through Phase 2 in obese patients, and the trial ended on insufficient effect size. Not a safety issue, not a mechanistic surprise. Just: it didnt move the number enough to justify continuation.

Fragment 191-203 is the simpler upstream progenitor of AOD9604. If the cleaner, better-optimized version failed to produce a meaningful clinical signal, it’s hard to construct a research argument for the cruder fragment. The distinction matters for bench work specifically: if you want to study GH-derived lipolytic signaling in adipocyte biology, Fragment 191-203 is a usable probe. You can ask real questions about functional dissociation of GH activities. But you’re asking questions about a mechanism that already had its clinical audition and produced a disappointing answer.

What we like: the conceptual separation of lipolytic from somatogenic GH activity is worth studying in adipocyte biology, and the compound is a legitimate research tool in that narrow context. What we don’t like: the literature is old, the mechanism is contested, the clinical translation failed, and there’s no compelling reason a bench scientist working today would reach for this over better-characterized beta-3 agonists for most lipolysis questions. It’s a historical tool with limited contemporary pull.

Novelty: 24
Mechanism promise: 42
In-category differentiation: 28
Evidence quality: 30
Translational signal: 20
Research bench value: 42

Rationale Fragment 191-203 has narrow bench utility as a probe for separating GH lipolytic from somatogenic signaling, but its literature peaked in the early 2000s, the mechanism remains contested, and the Phase 2 failure of its more-developed derivative AOD9604 is a decisive negative translational signal for the entire class.

C-terminal fragment of human growth hormone with lipolytic activity

A 13-residue C-terminal fragment of human growth hormone (residues 191 through 203), studied as a research tool for the lipolytic activity of GH separated from somatogenic and insulin-like effects.

Abstract

HGH Fragment 191-203 (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser; molecular weight 1495.78) is a 13-residue C-terminal fragment of human growth hormone (residues 191 through 203 of the mature 191-residue hGH polypeptide) developed as a research tool for separating the lipolytic activity of growth hormone from the somatogenic (growth-promoting) and insulinotropic activities. The full-length 191-residue hGH produces both lipolytic effects (acute fatty acid mobilization, chronic reduction of fat mass with a delay) and somatogenic and insulin-like effects (longitudinal bone growth in pediatric populations, insulin resistance in chronic exposure). Carboxypeptidase digestion of hGH produces fragments that retain selective subsets of these activities; the 191-203 fragment was characterized in the 1990s as a lipolytic-selective fragment in rodent adipocyte models and at the obese rodent in vivo level. The shorter fragment AOD9604 (KDC-MN; aod-9604), a tyrosine-conjugated 16-residue C-terminal fragment, was developed by Metabolic Pharmaceuticals (now Lateral) as a clinical agent in the same activity class and reached Phase 2 in obesity before discontinuation owing to insufficient effect size. Fragment 191-203 is the simpler underlying research tool from which AOD9604 was derived. The principal pharmacological signature is direct activation of beta-3 adrenergic receptor or downstream lipolytic signaling at the adipocyte level (the precise mechanism remains debated), increased fatty acid oxidation, and reduced de novo lipogenesis, without engagement of the GH receptor and without IGF-1 elevation. Plasma half-life is short (minutes) and the compound is administered subcutaneously. The compound is not approved by any regulatory authority and is sold only as a research-grade peptide; the principal published evidence base is from the 1990s and early 2000s and the clinical translation through AOD9604 did not produce a marketed agent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1340Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.